Home > Research > Clinical Trials > Phase IIb Trials

Current and Complete Phase II bTrials


Title Principal Investigator Study Coordinator Funder & Sponsor Publications

115616 (TUBERCULOSIS-018)



A phase IIb, double-blind, randomised, placebocontrolled study to evaluate the efficacy, safety and immunogenicity of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in adults aged 18-50 years, living in a TB endemic region.

PI: Assoc Prof Mark Hatherill

Sub Investigator:

Dr Michelle Tameris

D. van As Sponsor: Aeras  

Study Title Principal Investigator Study Coordinator Funders Publication

AERAS 485)C-020-485(MVA85A/

Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-Vaccinated, HIV-negative Infants Dr Michele Tameris  L.v d Merwe Partners: Aeras Global TB Vaccine Foundation, Oxford University, Emergent BioSolutions, Isis Innovation Ltd The Lancet Volume 381.